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Dysphagia in 6-Hydroxydopamine-Treated Rodents:
Behavioral and Manometric Studies
Abstract
　Dysphagia is a serious problem in patients with Parkinson’s disease (PD) because it causes 
malnutrition and aspiration pneumonia. In this study, dysphagia was examined in a PD rodent 
model induced with 6-hydroxydopamine (6-OHDA). Video-recording observation showed that 
the animals could gnaw food pellets but could not swallow them. However, they could swallow 
gelled food. L-DOPA administration did not improve the dysphagia. The result suggested 
that the upper esophageal sphincter (UES) may be impaired. Therefore, pressure of the UES 
was measured using a catheter with a small balloon in awake animals because UES pressure 
decreases under anesthesia. The pressure was unaltered in the PD model. Administration of 
neither haloperidol, which induces muscle rigidity, nor atropine, which relaxes esophageal 
smooth muscle, altered UES pressure. These results suggest that the pharyngeal phase in 
deglutition may be involved in dysphagia in the PD model. 
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　Dysphagia is a serious problem in patients 
with Parkinson’s disease (PD) because it induces 
malnutrition and aspiration pneumonia (Kalf et 
al. 2012). Although several reports have elucidated 
mechanisms of dysphagia in PD (Ertekin 2014; 
Johnston et al, 2001), an effective remedy 
against dysphagia has not been developed. In 
general, animal models are effective tools for 
clarifying the mechanisms of diseases. Although 
6-hydroxydopamine (6-OHDA)-treated rodents show 
dysphagia (Ungerstedt 1971), the precise mechanism 
has not been examined. Therefore, dysphagia in a 
6-OHDA rodent model of PD was examined in the 
present study. 
METHODS 
6-OHDA rodent models
　Male 10-to 12-week-old DDY mice (Kyudo 
Company, 883-1 Tateishimachi, Tosu, Saga 841-
0075), weighing 43-50 g, were used in a behavioral 
study. All surgeries were performed under 50 mg/
kg pentobarbital anesthesia (Nembutal, Abbott 
Laboratories, North Chicago, IL, USA). To induce 
degeneration of striatal dopaminergic terminals, 
a 40-Ǎg dose of 6-OHDA (Sigma, St. Louis, MO) 
was dissolved in 4 Ǎl 0.9 saline containing 0.01 
ascorbic acid and was manually infused bilaterally 
into the striatum (20 Ǎg per side, 40 Ǎg total per 
animal) using a 1-Ǎl Hamilton microsyringe at a 
rate of 1 Ǎl /min. 6-OHDA infusions were performed 
using a stereotaxic apparatus (Model 900, David 
Kopf Instruments, Pembroke Pines, FL) with the tip 
of the needle inserted vertically ï3.5 mm ventral to 
the bregma through a small hole in the skull 0 mm 
rostral and 2.2 mm lateral to the bregma. The needle 
was left in place for 2 min following the infusion 
to minimize the spread of the drug through the 
injection track. Desipramine hydrochloride (Sigma) 
at 20 mg/kg was dissolved in 40 propyleneglycol 
containing 10.5 ethanol and 0.34 mg/ml NaOH and 
intraperitoneally administered 20 min before the 
6-OHDA treatment to preserve noradrenergic nerve 
terminals in the striatum. Control animals received 
vehicle solution instead of 6-OHDA. 
　Male 13-week-old Wistar rats (Kyudo Company) 
weighing 430-480 g were used for the manometric 
study. To induce degeneration of bilateral striatal 
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dopaminergic terminals, a 120-Ǎg dose of 6-OHDA 
dissolved in 12 Ǎl 0.9 saline containing 0.01 
ascorbic acid (i.e., the concentration was 10 Ǎg/Ǎl) 
was manually infused bilaterally into the striatum 
using a 10-Ǎl Hamilton microsyringe at a rate of 1 
Ǎl/min. 6-OHDA infusions were performed using 
the stereotaxic apparatus with the tip of the needle 
inserted vertically ï6.0 mm from the surface of the 
skull. The first infusion site was at 2.0 mm rostral 
and 2.5 mm lateral to the bregma, the second was at 
0 mm rostral and 3.0 mm lateral to the bregma, and 
the third was at ï1.0 mm rostral and 4.0 mm lateral 
to the bregma. Therefore, six lesions were made in 
each rat, and the dose was 20 Ǎg/site. The needle 
remained in place for 2 min following the infusion. 
Desipramine hydrochloride was administered as 
described above. Control animals received the vehicle 
solution instead of 6-OHDA. 
Behavioral observation 
　Natural behavior, food handling, gnawing, 
mastication, and swallowing in the 6-OHDA-
treated mice were observed by video-recording in 
a transparent plastic cage 4 days after 6-OHDA 
injections. To investigate the ameliorating effect 
of L-DOPA on dysphagia, 6-OHDA-treated mice 
were administered 60 mg/kg L-DOPA + 15 mg/kg 
benserazide. L-DOPA (Sigma) was dissolved in 0.05 
N HCl, and benserazide HCl (Ro 4-4602, Santa Cruz 
Biotechnology) was dissolved in distilled water. Both 
drugs were injected simultaneously twice a day from 
the day after the 6-OHDA injection for 3 days. Then, 
the state of dysphagia was observed 30 min after the 
last administration of L-DOPA + benserazide. 
Manometric study
　The upper esophageal sphincter (UES) pressure 
was measured using a catheter equipped with a small 
plastic balloon  (Fig. 1) connected to a transducer 
(PAS-111, Star Medical, Arakawa, Tokyo) and 
recorded with an X-Y recorder (8U16, San-ei Sokki 
Co. LTD, Kodaira, Tokyo) 4 days after 6-OHDA 
injections. Preliminary experiments showed that the 
pressure was greatly reduced under ether anesthesia 
(Fig. 3B), and the pressure was therefore measured 
in awake animals. The rat was anesthetized with 
ether, and the catheter and a deflated balloon were 
inserted into the stomach. Insertion of the catheter 
into the esophagus after intubation with a plastic 
tube into the trachea was feasible. When the catheter 
reached the stomach, the balloon was Àlled with 0.3 
ml air. The rat was food-deprived for 24 hours before 
the measurement, since food in the stomach disrupts 
the pressure measurement. The rat was restrained 
manually by two persons, and the mouth was kept 
open by one pair of incisor bars from the stereotaxic 
apparatus. The catheter was slowly pulled out, and 
intra-esophageal pressure was recorded when the 
rat woke up from the anesthesia. The effect of drugs 
on esophageal pressure was examined with 2 mg/kg 
haloperidol and 1 mg/kg atropine. Haloperidol was 
intraperitoneally administered 45 min before (when 
the back muscle showed rigidity) the measurement of 
esophageal pressure. Atropine was intraperitoneally 
administered 15 min before the measurement of 
esophageal pressure. 
Immunoblotting
　The level of tyrosine hydroxylase (TH) protein 
in the striatum was measured to determine the 
degree of lesioning in 6-OHDA-treated rodents as 
previously described (Iwata et al, 2001). Rodents were 
decapitated just after the behavioral or manometric 
study ended, and the entire bilateral striata were 
removed onto an ice-cold plate. The striata were then 
sonicated in 250 Ǎl 1 SDS. A portion of the solution 
was used for a BCA protein assay (Pierce, Rockford, 
IL). TH protein was detected by immunoblotting, and 
the densities of bands 
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 　The present experiment was carried out after 
obtaining permission from the Committee of Animal 
Experimentation, Kagoshima Junshin University.
RESULTS
　Mice greatly lost body weight after 6-OHDA 
treatment (Fig. 2) because they could not eat food. 
Behavioral observations revealed that 6-OHDA-
treated mice could gnaw a food pellet, but the pellet 
spilled from the both sides of the mouth. These 
mice appeared to have difficulty with deglutition, 
but they were able to eat commercially available 
gel food (Tomlyon Nutri-StatTM). The average 
weight loss ratios 3 days after 6-OHDA treatment in 
L-DOPA-administered mice (n = 4) and in vehicle-
administered control mice (n = 5) were 21 and 
20, respectively. Video-recording observation 
showed that L-DOPA did not ameliorate 6-OHDA-
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induced dysphagia. Immunoblotting showed that TH 
contents in 6-OHDA-treated mice decreased to less 
than 20 of those in controls (Fig. 4), indicating that 
dopaminergic neurons were sufÀciently destroyed.
Intra-esophageal pressure was successfully 
recorded (Fig. 3A) and was significantly decreased 
under ether anesthesia (Fig. 3B). We observed no 
alterations in pressure between in 6-OHDA-treated 
rats and vehicle-treated rats. Neither haloperidol nor 
atropine affected the pressure (Table). The TH level 
in these rats was reduced to below 10 of control 
(Fig. 5), indicating that dopaminergic neurons were 
sufÀciently destroyed. 
DISCUSSION
　The 6-OHDA-treated mice could not swallow 
a food pellet, but could eat gelled food, indicating 
that these animals experienced dysphagia and not 
aphagia. In general, gel food is easier to swallow than 
regular meals for dysphagic patients. Therefore, the 
present rodent model is suitable for investigating 
dysphagia. L-DOPA did not ameliorate the dysphagia. 
Dysphagia in PD is not solely related to dopamine 
deÀciency (Hunter et al., 1997), and the Hoehn 	 Yahr 
score and the degree of dysphagia are not correlated 
(Nilsson et al, 1996). Furthermore, dopaminergic 
medication does not affect swallowing ability (Michou 
and Hamdy, 2010). In the present study, 6-OHDA was 
injected directly into the striatum, and desipramine 
pretreatment was performed before 6-OHDA 
treatment, indicating that the lesion was confined 
to the nigrostriatal dopaminergic system. These 
results suggest that dysphagia in PD is induced 
by impairment of the nigrostriatal dopaminergic 
pathway, but that it cannot be reversed by L-DOPA 
supplemental therapy. 
　The upper one-third of the esophageal muscle 
consists of striated muscle (Crary and Groher, 2003). 
6-OHDA-treated rats and haloperidol-administered 
rats showed muscle rigidity in their back muscles. 
Incomplete UES relaxation and reduced UES 
opening have been reported in PD (Ali et al, 1996; 
Higo et al, 2001). Therefore, we considered that 
UES pressure must have increased. However, the 
present study showed that the UES pressure was 
unaltered by dopaminergic denervation or haloperidol 
administration. 
　Atropine administration did not alter UES 
pressure in the present study. This is consistent with 
a study reporting no effects on UES relaxation or 
swallowing coordination with atropine (Knauer et al, 
1990).
　Technically, measuring intra-esophageal pressure 
in an awake rat was difÀcult. We had to keep the rat 
immobile because the pressure suddenly increased 
when the rat moved. The increased pressure of the 
UES was caused by an increase in tension from 
the esophageal wall to its proper pressure. For 
measurement of lower esophageal sphincter pressure 
in rats, a catheter of 4 Fr outer diameter is more 
suitable as no tension is present from the esophageal 
wall (Iino et al. 1983). In the present study, intra-
esophageal pressure in the dead animal (Fig. 3C) was 
not zero, which means that the balloons used detected 
tension in the esophagus. However, the tension was 
low enough to allow detection of esophageal pressure, 
especially in the region of the sphincter.    
　In summary, lesioning the bilateral dopaminergic 
system in the striatum is an appropriate model for 
dysphagia in PD. The dysphagia was not ameliorated 
by L-DOPA. UES pressure was unaltered in the 
model, which suggests that the pharyngeal phase in 
deglutition may be impaired in the model.  
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